Table 1 DMB administered after permanent coronary artery ligation mitigates adverse LV remodeling and improves cardiac function.

From: Intermittent Use of a Short-Course Glucagon-like Peptide-1 Receptor Agonist Therapy Limits Adverse Cardiac Remodeling via Parkin-dependent Mitochondrial Turnover

  

14 days post-MI

28 days post-MI

Vehicle n = 6

DMB n = 7

Vehicle n = 6

DMB n = 7

HR

bpm

432 ± 32.2

467 ± 50.1

446 ± 22.7

478 ± 37.3

EF

%

39.6 ± 4.5

49.0 ± 5.9*

32.9 ± 5.5

42.3 ± 5.3*

FS

%

19.3 ± 2.4

24.7 ± 3.5*

15.6 ± 2.8

21.0 ± 3.1*

LV Vol,d

uL

113.4 ± 39.7

96.9 ± 23.3

110.4 ± 38.5

125.0 ± 22.1

LV Vol,s

uL

69.3 ± 27.4

49.9 ± 14.0

75.4 ± 31.3

71.8 ± 12.8

LVID,d

mm

4.85 ± 0.73

4.56 ± 0.51

4.8 ± 0.7

5.1 ± 0.4

LVID,s

mm

3.93 ± 0.66

3.44 ± 0.46

4.1 ± 0.7

4.0 ± 0.3

LVPW,d

mm

1.04 ± 0.26

1.25 ± 0.31

1.2 ± 0.3

1.7 ± 0.3*

LVPW,s

mm

1.21 ± 0.24

1.48 ± 0.31

1.6 ± 0.4

2.1 ± 0.2*

Est. scar size

%

34.3 ± 3.0

28.8 ± 7.1

34.5 ± 6.8

30.3 ± 7.1

  1. Data are presented as mean ± standard deviation. HR, Heart rate; EF, Ejection Fraction; FS, Fractional Shortening; DMB, 2-Quinoxalinamine, 6,7-dichloro-N-(1,1-dimethylethyl)-3-(methylsulfonyl)-, 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline; LV Vol,d, Left Ventricle End-Diastolic Volume; LV Vol,s, LV End- Systolic Volume; LVID,d, LV Internal Diameter, Diastole; LVID,s, LV Internal Diameter, systole; LVPW,d, LV Posterior Wall thickness, diastole; LVPW,s, LV Posterior Wall thickness, systole. Naïve EF % 60.4 ± 6.7, FS % 29.3 ± 6.3 (n = 19). *p < 0.05 vs vehicle.
Back to article page